Everything below concerns lyophilization. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-09-06. Numbers and descriptions here follow the published literature rather than marketing material.
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
| Property | Value | Notes |
|---|---|---|
| Primary target | Growth hormone-releasing hormone receptor | Located on anterior pituitary somatotroph cells. |
| Receptor class | G protein-coupled receptor | Activation increases intracellular cyclic AMP. |
| Main downstream hormone | Growth hormone and insulin-like growth factor 1 | Growth hormone release precedes IGF-1 elevation. |
| Primary studied effect | Reduction in visceral adipose tissue | Measured by computed tomography in clinical trials. |
| Approximate half-life | 26–38 minutes after subcutaneous administration | Values vary by assay and study population. |
Because growth hormone is released in pulses, single measurements can misrepresent overall secretion. Investigators sometimes use repeated sampling or overnight profiles to capture the pattern rather than a single value. Provocative testing, in which a stimulus is given and the response is tracked over time, offers another way to characterize the axis. Each approach carries trade-offs between sensitivity, burden on the participant, and the influence of non-target variables.
Insulin-like growth factor 1 is produced largely in the liver in response to growth hormone signaling. Its concentration shifts over days rather than minutes, which makes it practical for tracking changes across a study period. Interpretation still depends on age, nutritional status, and concurrent illness, all of which independently affect the marker. Reference ranges are therefore stratified, and comparisons are usually made within an individual over time rather than against a single population threshold.
Assays for these markers differ in calibration and antibody specificity, so results from different platforms are not always interchangeable. Reported values can shift when a laboratory changes method, even without any biological change. Studies that span long periods or multiple sites often need cross-validation of assays. This methodological variability is a recognized limitation when comparing findings across published reports, and it remains a topic of ongoing standardization work.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
Practical handling centers on limiting moisture, oxygen, and temperature excursions. Lyophilized material is generally held at or below minus twenty degrees Celsius, protected from light and kept sealed until use. Once reconstituted, solutions are typically kept cold and used within a short window because hydrolysis and microbial growth both accelerate in liquid form. Repeated freeze-thaw cycles are avoided, since they promote aggregation. Vial contents should be inspected for particulates and clarity before analysis, and working aliquots are prepared to reduce the number of times the stock is opened.
Quantitation of the peptide relies mainly on reversed-phase high-performance liquid chromatography with ultraviolet detection, typically at 214 nanometers, where the peptide bond absorbs. Identity is confirmed by mass spectrometry, most often electrospray ionization coupled to liquid chromatography, and by peptide mapping after enzymatic digestion. Because related impurities differ only slightly in sequence or modification, method development emphasizes resolution rather than speed. Purity is usually reported as a percentage of the main peak area, with individual impurities listed separately when they exceed a defined reporting threshold.
Stability testing examines how the molecule changes under controlled stress. Thermal stress, light exposure, and extremes of pH are applied separately so that each degradation route can be attributed to a specific cause. The main observed changes are oxidation, deamidation, and aggregation into dimers or higher-order species. Accelerated studies at elevated temperature are used to estimate behavior over longer periods, though such extrapolation carries uncertainty. For a lyophilized powder, residual moisture and the choice of bulking agent strongly influence how quickly these changes appear.
On 27 April 1954, Queen Elizabeth II and her husband Prince Philip, Duke of Edinburgh visited the colony as part of their first Commonwealth tour. They were greeted by Governor of Aden Tom Hickinbotham and travelled to an enclosure to watch a military parade which included the RAF, Aden Protectorate Levies, Armed Police, Government Guards, the Hadhrami Bedouin Legion, and Somaliland Scouts. The visit saw Aden hold its first and only knighthood ceremony in which local leader Sayyid Abubakr bin Shaikh Al-Kaff was knighted whilst kneeling on a chair instead of bowing due to his Muslim faith. The Queen also knighted Claude Pelly, who was Commander-in-Chief of the Royal Air Force in the Middle East. A bronze plaque marks the foundation stone Elizabeth II laid for Al Jumhuriyah hospital during the visit. The hospital which was originally named after her until the end of British rule in 1967 was bombed by the Houthi movement in 2015, but remains open due to a UAE-funded restoration project.
Some quantum dots pose risks to human health and the environment under certain conditions. Notably, the studies on quantum dot toxicity have focused on particles containing cadmium and have yet to be demonstrated in animal models after physiologically relevant dosing. In vitro studies, based on cell cultures, on quantum dots (QD) toxicity suggest that their toxicity may derive from multiple factors including their physicochemical characteristics (size, shape, composition, surface functional groups, and surface charges) and their environment. Assessing their potential toxicity is complex as these factors include properties such as QD size, charge, concentration, chemical composition, capping ligands, and also on their oxidative, mechanical, and photolytic stability. Many studies have focused on the mechanism of QD cytotoxicity using model cell cultures. It has been demonstrated that after exposure to ultraviolet radiation or oxidation by air, CdSe QDs release free cadmium ions causing cell death. Group II–VI QDs also have been reported to induce the formation of reactive oxygen species after exposure to light, which in turn can damage cellular components such as proteins, lipids, and DNA. Some studies have also demonstrated that addition of a ZnS shell inhibits the process of reactive oxygen species in CdSe QDs.
*) The Bezirk Karl-Marx-Stadt was named Bezirk Chemnitz for a short period at both the beginning and end of the republic, corresponding with the renaming and reversal of the city Chemnitz. Between 10 May 1953 and 30 May 1990, both the city and Bezirk were named Karl-Marx-Stadt. **) East Berlin was not officially a Bezirk, but from 1961 was provided with the function of one.
Mushrooms can be used for dyeing wool and other natural fibers. The chromophores of mushroom dyes are organic compounds and produce strong and vivid colors, and all colors of the spectrum can be achieved with mushroom dyes. Before the invention of synthetic dyes, mushrooms were the source of many textile dyes. Some fungi, types of polypores loosely called mushrooms, have been used as fire starters (known as tinder fungi). Mushrooms and other fungi play a role in the development of new biological remediation techniques (e.g., using mycorrhizae to spur plant growth) and filtration technologies (e.g. using fungi to lower bacterial levels in contaminated water). There is an ongoing research in the field of genetic engineering aimed towards creation of the enhanced qualities of mushrooms for such domains as nutritional value enhancement, as well as medical use.
Sources: en.wikipedia.org
===== Parenchyma ===== Parenchyma (Greek, para – 'beside'; enchyma– infusion – 'tissue') is the bulk of a substance. In plants, it consists of relatively unspecialized living cells with thin cell walls that are usually loosely packed so that intercellular spaces are found between cells of this tissue. These are generally isodiametric in shape. They contain small number of vacuoles or sometimes they even may not contain any vacuole. Even if they do so the vacuole is of much smaller size than of normal animal cells. This tissue provides support to plants and also stores food. Chlorenchyma is a special type of parenchyma that contains chlorophyll and performs photosynthesis. In aquatic plants, aerenchyma tissues, or large air cavities, give support to float on water by making them buoyant. Parenchyma cells called Idioblast have metabolic waste. Spindle shaped fibers are also present in this cell to support them and known as prosenchyma, succulent parenchyma also noted. In xerophytes, parenchyma tissues store water.
== Flavors == Mint chocolate (or chocolate mint) is an individual flavor of chocolate, made by adding a mint flavoring, such as peppermint, spearmint, or crème de menthe, to chocolate. Mint chocolate can be found in a wide variety of confectionery items, such as candy, mints, cookies, mint chocolate chip ice cream, hot chocolate, and others. It is also marketed in a non-edible format in cosmetics with a distinctive mint fragrance. The chocolate component can be milk chocolate, regular dark chocolate, or white chocolate; due to this, mint chocolate has no one specific flavour, and so each chocolate-plus-flavor combination can be unique. The U.S. National Confectioners Association lists February 19 as "Chocolate Mint Day".
=== 2011: Rebuilding and named the Army Reserve === In 2010, the government set up a commission, chaired by General Sir Nicholas Houghton, to review the state of the reserves and to design their future. The commission reported in July 2011. It found that, despite their operational commitments, the reserves had been neglected: some estimates put its trained and active strength as low as 14,000. There had been 'a failure to resource recruiting and good training, especially collective training; to offer career progression; to update operational roles; to permit deployment in formed sub-units and therefore offer command opportunities' Its recommendations included that a new target of 30,000 trained strength by 2020 be set. The government published the report on 18 July with an immediate promise of £1.5 billion funding over ten years. In October 2012 MoD announced a new name for the Territorial Army, its current name, the Army Reserve. Most of the recommendations of the commission were adopted in the White Paper July 2013 including the critical importance of providing operational and training opportunities for formed units and sub-units. Some aspects required legislation and were introduced in the Defence Reform Act (2014). These included the name change, reforms in mobilisation arrangements and in employer compensation.
Sources: en.wikipedia.org
Acquired C1 esterase inhibitor deficiency Acute urticaria Adrenergic urticaria Anaphylaxis Aquagenic urticaria Autoimmune urticaria Cholinergic urticaria Chronic urticaria (ordinary urticaria) Cold urticaria Dermatographism (dermographism) Episodic angioedema with eosinophilia (Gleich's syndrome) Exercise urticaria (exercise-induced urticaria) Galvanic urticaria Heat urticaria Hereditary angioedema (Quincke's edema) Localized heat contact urticaria Mast cell-independent urticaria Physical urticaria Primary cold contact urticaria Pressure urticaria (delayed pressure urticaria) Reflex cold urticaria Schnitzler syndrome Secondary cold contact urticaria Solar urticaria Systemic capillary leak syndrome Urticarial allergic eruption Urticaria-like follicular mucinosis Vibratory angioedema
Specific industries, such as the airline, healthcare and food industries, have special concerns. Due to rising rates of obesity, airlines face higher fuel-costs and pressures to increase seating-width. In 2000, the extra weight of passengers with obesity cost airlines US$275 million. The healthcare industry has invested in special facilities for handling patients with class III obesity, including special lifting equipment and bariatric ambulances. Litigation accusing restaurants of causing obesity increases restaurant costs. In 2005, the US Congress discussed legislation to prevent civil lawsuits against the food industry in relation to obesity; however, it did not become law. With the American Medical Association's 2013 classification of obesity as a chronic disease, it is thought that health-insurance companies will more likely pay for obesity treatment, counseling and surgery, and the cost of research and development of adipose-treatment pills or gene-therapy treatments should become more affordable if insurers help to subsidize their cost. The AMA classification is not legally binding, however, so health insurers still have the right to reject coverage for a treatment or procedure. In 2014, The European Court of Justice ruled that morbid obesity is a disability. The Court said that if an employee's obesity prevents "full and effective participation of that person in professional life on an equal basis with other workers", then it shall be considered a disability and that firing someone on such grounds is discriminatory.
== Research and partnerships == Mondobiotech investigated whether information already published about naturally occurring human substances could suggest new uses in rare diseases. A 2010 case study by researchers at the University of St. Gallen described its use of scientific literature, external researchers and laboratories, and licensing partners instead of maintaining a conventional in-house laboratory operation. Financial news reporting also described the company's approach as searching medical databases for drug candidates and licensing rights to other companies. In 2002, Mondobiotech and InterMune agreed to collaborate on interferon gamma-1b research for pulmonary diseases, including asthma; the arrangement also covered specified patent rights relating to idiopathic pulmonary fibrosis. In 2006, Biogen Idec licensed rights to develop aviptadil for pulmonary arterial hypertension. The agreement included a US$7.5 million upfront payment and up to US$30 million in possible development and commercialization milestones; the milestone amount was conditional, not a payment already received. Biogen stated in a later regulatory filing that it ended its participation in the aviptadil development program in December 2009. In February 2010, Mondobiotech entered a partnership with Lung Rx, a subsidiary of United Therapeutics, for further development of aviptadil. The company also agreed in 2009 to have Bachem develop and manufacture peptides for its research programs.
Although the exact reason these proteins become targets of the immune system is not completely understood, they are thought to become exposed during inflammation or other changes within the cell. Once immune tolerance is lost, B lymphocytes produce anti-U1 RNP antibodies that recognize components of the U1 snRNP complex. While these antibodies are primarily used as biomarkers for autoimmune disease, studies continue to investigate whether they also contribute to inflammation and disease progression.
Sources: en.wikipedia.org
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Binding stimulates cyclic AMP signaling and growth hormone secretion. This is the same receptor used by endogenous GHRH.
It does not act directly on adipose tissue as a primary mechanism. Instead, it increases endogenous growth hormone, which then influences lipolysis and fat distribution. The reduction in visceral fat is an indirect pharmacodynamic effect.
Tesamorelin acts upstream at the pituitary to amplify natural pulsatile growth hormone release. Growth hormone injections provide exogenous hormone and bypass pituitary regulation. The two approaches therefore differ in feedback control and hormonal dynamics.
It mirrors the 44-residue form of human growth hormone-releasing hormone. A hexenoyl group on the N-terminal tyrosine distinguishes it from the unmodified hormone. The change is intended to improve resistance to enzymatic breakdown.